Article
Madison, WI-There are no immediate effective treatments for most optic neuropathies, which result in the irreversible death of retinal ganglion cells.
Galimedix Therapeutics initiates phase 1 trial of oral GAL-101
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Cambium Bio completes funding to help advance dry eye disease treatment
Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD
Risk factors for cataracts in patients with diabetes mellitus
VivaVision Biotech reports positive Phase 2 trial results of VVN461 for postoperative inflammation treatment following cataract surgery